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ABSTRACT
Objective: Placebo response in stud-
ies of binge eating disorder (BED) has
raised concern about its diagnostic
stability. The aims of this study were
(1) to compare placebo responders
(PRs) with nonresponders (NRs); (2) to
investigate the course of BED follow-
ing placebo response; and (3) to
examine attributions regarding pla-
cebo response.
Method: The baseline placebo run-in
phase (BL) was part of a RCT investigat-
ing sibutramine hydrochloride for BED; it
included 451 participants, ages 19–63,
diagnosed with BED. Follow-up (FU) in-
cluded 33 PRs.
Results: In this study, 32.6% of partici-
pants responded to placebo (PRs ¼ 147;
NRs ¼ 304). PRs exhibited signiﬁcantly
less symptom severity. At FU (n ¼ 33),
many PRs reported continued symptoms.
Conclusion: PRs exhibited signiﬁcantly
less severe pathology than NRs. Placebo
response in BED may transitory or incom-
plete. The results of this study suggest
variable stability in the BED diagnosis.
V V C 2006 by Wiley Periodicals, Inc.
Keywords: binge eating disorder; pla-
cebo response; eating disorders; psycho-
pathology
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Introduction
Binge eating disorder (BED) consists of recurrent
episodes of binge eating in which large amounts of
food are eaten with accompanying loss of control.
1
Obesity is prevalent among individuals with BED.
2–4
In recent years, there has been a noteworthy in-
crease in pharmacotherapy studies for BED, primar-
ily involving antidepressants, appetite suppressants,
and anticonvulsant agents.
5 Results from these
studies suggest a promising role for pharmacother-
apy as a treatment component for BED.
5
Placebo-controlled pharmacological studies of BED
have revealed highly variable, and often marked, rates
of short-term placebo response.
6,7 Placebo response
in BED has been deﬁned by a marked reduction in
binge eating symptomatology during placebo admin-
istration. A review of pharmacological treatments for
BED by Carter et al.
5 indicates a mean placebo
r e s p o n s er a t eo f3 3 % .T h er a t eo fp l a c e b or e s p o n s ei n
BED is similar to that in other major psychiatric ill-
nesses, including major depressive disorder and bipo-
lar disorder,
8–10 but not bulimia nervosa (BN), which
has a markedly lower rate of placebo response than
that associated with other psychiatric illnesses.
11 A
meta-analysis of placebo response in unipolar de-
pression indicated a mean placebo response rate of
32.8%.
9 A meta-analysis of bipolar disorder revealed a
mean placebo response rate of 29%.
8
Although placebo response occurs across a range
of psychiatric diagnoses, investigation of the phe-
nomenon in BED may provide increased clarity
regarding the course and stability of the diagnosis
and may be relevant to the presently unsettled
nosological status of BED.
12–14 Rates of placebo
response in BED suggest that there may be hetero-
geneity among ostensibly similar groups of patients.
Fairburn and colleagues’
15 natural course study of
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REGULAR ARTICLEBN and BED found that after 5 years, only 18% of
the BED participants still had an eating disorder,
compared with 51% of the BN cohort. In contrast,
preliminary results from the McKnight study
reported by Crow et al.
16 indicated a higher degree
of stability of eating disorder symptoms in BED,
with 93% of participants still having an eating disor-
der at 1-year follow-up. At issue is whether BED is a
syndrome in need of active treatment or a condition
that is likely to remit on its own.
To our knowledge, the present study is the ﬁrst
systematic investigation of placebo response in
BED. The primary aims were to (1) compare pre-
treatment characteristics of placebo responders
(PRs) and nonresponders (NRs); (2) to investigate
the course of BED symptomatology among PRs fol-
lowing placebo response; and (3) to examine PRs’
attributions regarding the remission and/or return
of their binge eating symptoms.
Method
This study occurred as part of a multicenter, randomized
controlled trial to test the efﬁcacy and safety of sibutr-
amine hydrochloride for the treatment binge eating dis-
order (BED).
17 Data collection took place in two phases,
baseline (BL) and follow-up (FU), separated by approxi-
mately 1 year (1999–2000). BL data were collected as part
of the sibutramine efﬁcacy trial, which took place at 18
centers in the United States. From the 18 sites in the orig-
inal study, a subset of ﬁve sites were elected to partici-
pate in a follow-up study. All research was reviewed and
approved by an institutional review board. The primary
aim of the FU study was to assess the course of eating
disorder symptomatology among PRs approximately 1-
year post-exclusion from the treatment phase of the
sibutramine trial (see Figure 1 for study design).
BL Phase
Participants. All participants met full DSM-IV research
criteria for BED.
18 The diagnosis of BED was established
using the Eating Disorder Examination (EDE),
19 BED
diagnostic version. Participants had to be between ages
18–65, with a body mass index (BMI) of <45 kg/m
2.
Exclusion criteria included an eating disorder (non-BED)
within the previous 6 months, current use of psychoac-
tive or weight loss agents or of medications potentially
interfering with drug absorption, current insulin use, a
history of alcohol or drug abuse (previous 12 months), a
current psychiatric condition being treated with a psy-
choactive agent, major depressive disorder, and history
of psychosis, bipolar disorder, or suicide attempts.
17
Classiﬁcation of placebo response occurred after
4 weeks of single-blind placebo administration. Individu-
als who continued to meet BED diagnostic criteria and
who did not experience marked decreases in binge eating
were included in the sibutramine trial. These participants
were classiﬁed as placebo nonresponders (NRs). Partici-
pants who no longer met BED diagnostic criteria or who
experienced a marked reduction in binge eating (total
number of binge episodes for the previous week was
 25% of that for the week preceding the beginning of the
placebo run-in phase) were classiﬁed as PRs and were
excluded from the sibutramine trial.
Measures. Eating disorder symptomatology was asse-
ssed at screening and FU using the BED diagnostic ver-
sion of the EDE,
19 an investigator-based, semi-structured
interview designed to provide a complete assessment of
BED. It is derived from the EDE 12.0D,
19 which has well-
established reliability and validity.
20–24 It obtains a 6-
month history of objective binge eating episodes and
other episodes of overeating, compensatory behaviors,
and attitudes associated with binge eating (i.e., impor-
tance of weight and shape) and demonstrates good-to-
excellent reliability in the assessment of BED.
25
The EDE allows binge eating episodes to be catego-
rized with respect to: (1) the amount of food eaten and
(2) loss of control. Eating episodes that include an
‘‘unambiguously large’’ quantity of food (determined by
the interviewer) and that occur with a loss of control are
classiﬁed as objective bulimic episodes (OBEs). Eating
episodes in which the interviewee reports a subjective
sense of having overeaten (but are not objectively large)
and that occur with a loss of control are classiﬁed as
subjective bulimic episodes (SBEs). Occasions of eating
FIGURE 1. Study Design
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control are classiﬁed as objective overeating (OO). Varia-
bles derived from the EDE included the average fre-
quency of OBEs over the previous 6 months, as well as
reported binge days and episodes (objective and subjec-
tive), OO days and episodes, and importance of weight
and shape over the previous 28 days.
B i n g ee p i s o d e sw e r er e c o r d e dd a i l yb yp a r t i c i p a n t sf o r
4 weeks using a binge episode diary. Binge episodes were
deﬁned as ‘‘episodes of overeating during which you feel
out of control’’.
17 Participants recorded the time, content,
ratings of loss of control (using a Likert-type scale), and dis-
tress related to all such episodes. These episodes were then
evaluated in a clinical interview by an investigator using
the overeating section of the EDE. Episodes determined to
be OBEs were then recorded on case report forms.
Quality of life was measured using the Impact of
Weight on Quality of Life Questionnaire (IWQOL-Lite).
26
The IWQOL-Lite is a 31-item, self-report measure which
demonstrates strong psychometric properties and as-
sesses the impact of overweight status on quality of life,
including ﬁve speciﬁc domains of quality of life: Work,
Public Distress, Sexual Life, Physical Function, and Self-
Esteem.
26 Higher scores on the IWQOL-Lite indicate
greater impairment.
Procedures.
1. Screening: All participants provided written in-
formed consent and received a physical exam,
measurement of height and weight, and completed
the EDE interview within the 2 weeks before pla-
cebo administration.
17
2. Placebo run-in (week-4 and week-2): Two visits
occurred at 2-week intervals during the 4-week pla-
cebo administration period. Participants received a
medical evaluation and submitted 2-week binge
episode diaries for review. Any adverse medical
events or medication changes were documented. At
the ﬁrst visit, participants completed the IWQOL-
Lite and received a 4-week supply of placebo medi-
cation.
3. Baseline visit (Day 1): All participants received a
medical evaluation and returned 2-week binge epi-
sode diaries for review. Participants determined to
be PRs were excluded from further participation in
the sibutramine study; NRs not otherwise excluded
were randomized.
Statistical Analysis I. All statistical analyses were con-
ducted using Stata, version 9.1, or SPSS for Windows, ver-
sion 11.5. Independent sample t tests were conducted to
investigate pretreatment differences between PRs and
NRs for each of the following variables separately: age,
BMI, days and episodes of OBEs and SBEs for the preced-
ing 28 days, average OBE days per week in the previous 6
months, OO days and episodes (previous 28 days),
importance of weight (previous 28 days), importance of
shape (previous 28 days), and quality of life (IWQOL-Lite
total and subscale scores). The difference in gender was
evaluated by Fisher’s exact test. Logistic regression was
performed to investigate whether the EDE variables pre-
dicted PR status (controlling for age [categories for quin-
tiles of the age distribution], gender, and BMI [categories:
<30, 30–34, 35–39, and  40]); the values of the con-
tinuous predictor variables were scaled to SD units based
on the sample distribution, so that the resulting odds
ratio (OR) from logistic regression represented the OR for
each 1 SD unit increase in the predictor. Alpha was set at
.05, two-tailed.
a
Follow-Up (FU) Phase
Participants. PRs at participating sites were interviewed
in person (or by phone if unavailable in person) approxi-
mately 1 year after study exclusion to assess eating dis-
order symptomatology, attributions regarding placebo
response, and additional treatment obtained.
Measures. Eating disorder symptomatology was assessed
using the BED diagnostic version of the EDE,
19 modiﬁed
to include assessment of all months following exclusion
from the trial. PRs’ attributions for (1) initial placebo
response and (2) subsequent remission and/or (3) return
of eating disorder symptomatology were obtained through
a three-question interview (available upon request) de-
veloped for this study. Participants could provide multi-
ple attributions.
Based on a review of participant responses and the lit-
erature regarding the etiology and treatment of binge eat-
ing, the ﬁrst author generated response categories for the
classiﬁcation of attributions by two trained, independent
raters. Cohen’s kappa (k) was calculated to assess inter-
rater agreement. With the exception of the ‘‘other’’ cate-
gory, the classiﬁcations demonstrated moderate to excel-
lent interrater reliability (k ¼ .6–1.0). On items with
imperfect agreement, the two raters (supervised by the
ﬁrst author) conferred to achieve consensus.
Data on additional treatment obtained were obtained
by interview with study personnel.
Procedures. FU participants were interviewed approxi-
mately 1 year (range 8–18 months; m ¼ 13.3 months,
median ¼ 12 months) following exclusion from the
sibutramine trial. They completed the EDE and the attri-
aGiven the exploratory nature of the analyses, corrections for
multiple comparisons were not performed.
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ment information.
Statistical analyses II. To investigate sample representa-
tiveness, two-tailed independent sample t tests were used
to compare the eating disorder symptomatology of the FU
sample (at BL) with that of nonparticipating PRs. EDE vari-
ables included in these analyses were OBE days/episodes,
SBE days/episodes, 6-month OBE average (days per week),
OO days/episodes, importance of weight, and importance
of shape.
Descriptive statistics of EDE variables were used to
investigate the course of eating disorder symptomatology
following placebo response. Frequencies were calculated
for the following variables: OBE days (previous 28 days),
SBE days (previous 28 days), and 6-month OBE average
(days/week). The analytic approach taken to the attribu-
tional and additional treatment data was also descriptive.
Alpha was set at .05, two tailed.
b
Results
BL Phase
Participant Flow. Participants (n ¼ 543) entered the
single-blind placebo run-in phase at week-4; 92
dropped out of the study before baseline assess-
ment (day 1). Of the remaining 451 participants,
147 (32.6%) were classiﬁed as PRs and 304 (67.4%)
were classiﬁed as NRs (see Figure 2).
Participant Characteristics. PRs and NRs did not sig-
niﬁcantly differ with respect to age (p ¼ 0.86), BMI
(p ¼ 0.10), or gender (p ¼ 1.0). The mean (SD) for
age was 41.8 (9.6) years, and BMI was 35.3 (5.3) kg/
m
2; 90.3% of subjects were female.
Pretreatment Characteristics: PRs versus NRs.
1. Eating disorder symptomatology: PRs and NRs
signiﬁcantly differed with respect to objective
and subjective binge eating and overvaluation
of weight and shape. Overall, PRs had signiﬁ-
cantly fewer OBEs on fewer days but reported
more SBEs than did NRs. PRs reported signiﬁ-
cantly less emphasis on shape and weight in
self evaluation than NRs (see Table 1).
Cohen’s d effect sizes for the signiﬁcant group
differences were .3–.4.
2. Additional pretreatment differences:P R sr e -
ported signiﬁcantly better overall and domain-
speciﬁc quality of life (public distress, sex, and
work subscales) than NRs (see Table 2). Cohen’s
d effect sizes for the signiﬁcant group differ-
ences were .2–.3.
Prediction of PR Status. Logistic regression was con-
ducted to investigate whether variables hypothe-
sized to be related to the stability of BED predicted
PR status. The ﬁve signiﬁcant predictors of PR were
the OBE days, OBE episodes, 6-month OBE aver-
age, SBE episodes, and importance of shape. For
OBE days, OBE episodes, 6-month OBE average,
and importance of weight, increasing values were
associated with lower odds of PR, whereas with
SBE episodes, an increasing value was associated
with higher odds of PR. Speciﬁcally, for each 1 SD
unit increase in the value of the predictor, the OR
(95% conﬁdence interval; P-value) for PR was: 0.75
(0.60–0.92; 0.006) for OBE days; 0.68 (0.54–0.86;
0.001) for OBE episodes; 0.69 (0.56–0.85; < 0.001)
for 6-month OBE average; 1.30 (1.1–1.6; 0.012) for
SBE episodes; and 0.76 (0.62–0.92; 0.007) for the
importance of shape. SBE days, OO days/episodes,
and importance of weight were not signiﬁcant pre-
dictors.
FU Phase
FU Participant Flow and Characteristics. Thirty-three
PR subjects participated in the FU study, which
represented 22.5% of the 147 total PR subjects and
58.9% of the 56 PR subjects eligible to participate in
the ﬁve study centers conducting the PR study.
Comparisons between PRs participating in the FU
study (n ¼ 33) and nonparticipating PRs (n ¼ 133)
indicate that the groups did not signiﬁcantly differ
with respect to any predictors of PR status (i.e.,
OBE days/episodes, 6-month OBE average, SBE
FIGURE 2. Participant Flow
bGiven the exploratory nature of the analyses, corrections for
multiple comparisons were not performed.
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differ, however, with respect to importance of weight.
At study entry, the FU sample reported signiﬁcantly
lower importance of weight than the nonparticipat-
ing PRs. (mean [SD] of 3.8 [1.6] versus 4.1 [1.2],
respectively; p ¼ 0.001). Tests of the remaining varia-
bles revealed no other signiﬁcant differences.
Eating Disorder-Related Symptomatology. At FU, 18
(54.5%) PRs were abstinent from OBEs in the pre-
vious month. Four PRs (12.1%) reported 1–3
OBE days in the past month, 8 (24.2%) reported 4–7
OBE days and 3 PRs (9.1%) reported 8 or more OBE
days. Ten participants (30.3%) were abstinent from
both OBEs and SBEs in the most recent month (see
Table 3). Twenty-three participants (69.7%) re-
ported SBEs in the past month. Over the previous
6 months, 56.3% of the sample reported OBEs on
an average of 4 or more days per month; 35% re-
ported diagnostic levels of binge eating (minimum
average of 2 OBE days/week).
Additional Treatment. Most of the FU sample (61%)
received additional treatment during the follow-up
period. Of treatment-seekers, 31.4 % (n ¼ 10)
obtained weight loss treatment, 27.3% (n ¼ 9)
received pharmacotherapy, 12.5% (n ¼ 4) received
individual psychotherapy, and 9.4% (n ¼ 3) joined
support groups. Thirty-ﬁve percent (n ¼ 7) sought
multiple treatments.
Relationship Between Abstinence from Binge Eating and
Additional Treatment. Of the 18 participants absti-
nent from OBEs at month 1, 61.1% (n ¼ 11)
received additional treatment. Of the 10 participants
who were OBE and SBE abstinent at month 1, 50%
(n ¼ 5) received additional treatment.
Obtaining additional treatment was the top reason
cited by PRs for improvement in their binge eating
symptoms.
PRs’ Attributions
1. Initial placebo response: FU PRs (n ¼ 33) most
frequently attributed their placebo response
to increased awareness of their eating (43.8%),
increased accountability to others (i.e., study
TABLE 1. Pretreatment EDE comparisons
Variable
PR (n ¼ 147)
Mean (SD)
NR (n ¼ 304)
Mean (SD) td f
a p Value Effect Size d
OBE days (previous 4 weeks) 14.9 (6.6) 16.9 (7.3) 2.83 446 0.005 0.3
OBE episodes (previous 4 weeks) 18.8 (11.2) 23.2 (13.7) 3.38 443 <0.001 0.4
6-month OBE average (days/week) 3.6 (1.7) 4.2 (1.6) 3.54 448 <0.001 0.4
SBE days (previous 4 weeks) 5.8 (8.4) 4.3 (7.5)  2.70 446 0.007 0.3
SBE episodes (previous 4 weeks) 8.1 (13.3) 4.3 (7.5)  1.88 447 0.061 0.2
Importance of weight (previous 4 weeks) 4.4 (1.4) 4.6 (1.3) 1.33 449 0.18 0.1
Importance of shape (previous 4 weeks) 4.5 (1.3) 4.9 (1.1) 2.99 449 0.003 0.3
OO
b days (previous 4 weeks) 1.9 (5.3) 1.9 (6.8) 0.05 447 0.96 0.0
OO episodes (previous 4 weeks) 1.9 (5.6) 2.0 (7.1) 0.16 447 0.87 0.0
Note: EDE ¼ eating disorder examination; OBE ¼ objective bulimic episode; SBE ¼ subjective bulimic episode; OO ¼ objective overeating; PR ¼ placebo
responder; NR ¼ nonresponder; SD ¼ standard deviation; df ¼ degrees of freedom, d ¼ standardized difference between 2 means.
adf varies among variables due to missing data.
bObjective overeating: eating an unambiguously large amount of food with no accompanying loss of control.
TABLE 2. IWQOL-Lite
a Pretreatment comparisons
IWQOL Scores
PR (n ¼ 147)
Mean (SD)
NR (n ¼ 304)
Mean (SD) td f
b p Value Effect Size d
Total 70.9 (19.8) 76.4 (22.9) 2.38 420 0.018 0.3
Public distress 8.9 (3.8) 10.1 (4.4) 2.66 443 0.008 0.3
Sex 9.3 (4.1) 10.3 (4.6) 2.14 433 0.033 0.2
Work 7.7 (2.8) 8.5 (3.4) 2.45 439 0.015 0.3
Physical function 24.3 (8.6) 25.8 (9.9) 1.58 437 0.12 0.2
Self esteem 20.9 (6.8) 21.6 (7.1) 1.00 422 0.32 0.1
Note: PR ¼ placebo responder; NR ¼ nonresponder; SD ¼ standard deviation; df ¼ degrees of freedom.
aHigher scores on the Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite) indicate greater impairment.
bdf varies among variables due to missing data.
TABLE 3. Binge eating at follow-up
Binge Days
(past 28 days) Frequency (n)%
0 OBEs 18 54.5
1–3 OBEs 4 12.1
4–7 OBEs 8 24.2
8þ OBEs 3 9.1
0 OBEs and 0 SBEs 10 30.3
Note: OBE ¼ objective bulimic episode;SBE ¼ subjective bulimie episode.
JACOBS-PILIPSKI ET AL.
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social support (18.8%), and motivation to
change (18.8%). Other responses included
belief in the (placebo) medication, positive
affect, positive expectations, being busy with
other activities, and other/don’t know.
2. Return of binge eating symptoms:M o s tP R s
(89%, n ¼ 29) reported experiencing binge eat-
ing symptoms during the follow-up period.
The most common attributions for the return
of binge eating were stress (20.7%), negative
affect (17.2%), and ‘‘other’’ (17.2%). Additional
attributions included decreased motivation,
personal failing, habit, decreased awareness,
reduced accountability to others, reduced
social support, increased food availability, dis-
continuation of self-monitoring, the nature of
BED, lack of medication, and other/don’t know.
3. Improvement in binge eating symptoms: Partici-
pants who reported improvement in binge eat-
ing (n ¼ 15; 45%) most commonly attributed it
to receiving additional treatment (26.7%), being
busy with other activities (20%), and health
concerns (20%). Other responses included self-
monitoring, social support, positive affect, mo-
tivation, appearance concerns, and other.
Discussion
Similar to the rates reported for the controlled
phases of other pharmacotherapy trials, approxi-
mately one third of the participants in the BL sam-
ple responded to placebo. With respect to eating
disorder symptomatology and quality of life, PRs
exhibited signiﬁcantly less severe pathology than
NRs. Nevertheless, within the time period between
BL and FU, most of those PRs assessed at FU
reported binge eating symptoms; more than one
third met the BED diagnosis. PRs cited varied rea-
sons for changes in their binge eating.
The 32.6% placebo response rate in this study is
similar to mean placebo response rates reported in
the treatment phases of trials involving other major
psychiatric illnesses, including major depressive
disorder
8–10,12 and bipolar disorder.
8,27,28 It is also
consistent with the placebo response rate recently
reported in the treatment phase of another trial
investigating the use of sibutramine for BED
29 and
to other placebo controlled trials for BED.
Comparisons between PRs and NRs reveal a
consistent pattern of differences in eating dis-
order symptoms. NRs demonstrated signiﬁcantly
greater frequency and severity of OBEs than PRs
and signiﬁcantly more concerns about shape.
The importance of binge size with respect to the
diagnosis of BED has been debated.
30 PRs were sig-
niﬁcantly more likely to experience SBEs than NRs,
but signiﬁcantly less likely to have OBEs days or
episodes. Binge size thus appears to discriminate
participants who respond to placebo from those
who do not. Logistic regression results suggest that
a pattern of greater OBE days, OBE episodes, and
6-month OBE average, as well as a lower number of
SBEs and higher importance of shape may reduce
the odds of placebo response.
Obesity is highly prevalent among individuals with
BED, affecting approximately 65% of individuals with
BED.
3 Despite similar levels of obesity, the groups
demonstrated signiﬁcant differences with respect to
its impact on quality of life. The data suggest that the
deleterious impact of binge eating on quality of life
in obese individuals is signiﬁcantly greater than the
negative impact of weight alone.
31 The poorer qual-
ity of life among NRs may be related to greater
severity of their binge eating symptoms.
Although slightly more than one half of the FU
sample reported no OBEs in the month immediately
before the FU assessment, nearly 70% did report a
loss of control over their eating. The signiﬁcance of
loss of control experiences among obese individuals
with a history of BED requires further investigation.
With respect to the diagnostic status of the FU
sample, approximately 35% of the participants
experienced binge eating consistent with a BED
diagnosis ( 2 OBE days/week for 6 months). Fifty-
six percent of the participants experienced OBEs an
average of at least 4 days per month over 6 months.
Although this does not meet the diagnostic thresh-
old for BED, data suggest that individuals with sub-
threshold BED (those whose binge size and/or fre-
quency is below the diagnostic threshold) experi-
ence weight and shape concerns, psychiatric
distress, and seek treatment for their eating and
weight problems at rates similar to those of individ-
uals diagnosed with BED.
32
Potentially indicative of participants’ continued
distress over their eating is the considerable per-
centage (61%) that obtained additional treatment.
The treatments most frequently obtained were
behaviorally-based weight loss treatment and phar-
macotherapy (e.g., sibutramine).
Participants retrospectively attributed their pla-
cebo response to personal factors (such as in-
creased awareness of their eating behavior, self-
monitoring, increased motivation to change their
eating behavior) and interpersonal factors (having
PLACEBO RESPONSE IN BED
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most commonly cited reasons for the resumption
of binge eating were environmental (e.g., stress)
and personal (such as depressed mood, decreased
motivation, sense of personal failing, decreased
awareness of eating behavior, habit). Reasons cited
for continued improvement following the initial
placebo response were largely environmental (e.g.,
obtaining additional treatment, participating in
other activities) and personal (i.e., health concerns,
self monitoring, positive affect, high motivation,
appearance concerns).
Several limitations of the present study should be
considered. Nonspeciﬁc treatment effects (i.e., con-
tact with study personnel) potentially confound the
measurement of placebo response,
10 as do other fac-
tors, such as natural course of illness, expectation
effects, and regression to the mean.
8–10,28,33 Similar
to other pharmacological studies of BED, the study
protocol asked all participants to monitor their eat-
ing behavior during the study. The self-monitoring
component of the present study was designed to
reduce reactivity (e.g., both groups self-monitored);
nevertheless, the act of self-monitoring may have
affected participants’ eating behavior. These data
may also have been inﬂuenced by selection bias; all
participants sought treatment and consented to
participate in a placebo-controlled trial, potentially
indicating expectation effects regarding placebo.
Because the assessment of initial PR was coded cat-
egorically (PR or not PR), no data on percentage
reduction in binge eating following initial PR are
available. FU participants consented to be reinter-
viewed and may have experienced superior out-
comes compared with PRs who were not available
for follow-up assessment. The entry criteria for the
study (BMI <45 kg/m
2, no comorbid disorders)
may have excluded participants with more severe
psychopathology and poorer prognoses. Finally,
additional participants may have responded to pla-
cebo during the subsequent double-blind phase;
examination of these individuals could potentially
elucidate the fuller range of placebo response in
BED. Although the FU sample appears represent-
ative with respect to predictors of placebo re-
sponse, a larger sample assessed at discrete inter-
vals is required to increase the inferential power of
these ﬁndings.
Conclusion
Use of a placebo control has become the sine qua
non of the randomized controlled trial.
33 Individu-
als with BED who respond to placebo appear to
demonstrate less severe eating disorder psychopa-
thology and less impairment in quality of life than
do nonresponders (NRs) and may potentially bene-
ﬁt from briefer, less intensive interventions than
NRs. Short-term intervention with a placebo, how-
ever, appears of little value with respect to the
long-term management of these binge eating prob-
lems. Even among individuals with fewer complica-
tions related to obesity and comorbid psychopa-
thology, BED may be a refractory condition.
The authors are grateful to Therese Gregory-Bills for her
participation in this project
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